Updated:
Longevity Vision Holding
Longevity Vision Holding is a New York venture firm investing exclusively in companies that use AI and biology to extend healthy human lifespan.
Longevity Vision Holding
Longevity Vision Holding operates from New York with a concentrated thesis: aging is the root cause of the most costly diseases, and technology can intervene before damage becomes pathology. The firm funds companies that measure biological age, reprogram cells, or deploy AI to discover therapies for age-related decline. Its mandate spans diagnostics, therapeutics, and digital health, with an emphasis on interventions that extend healthspan rather than simply lifespan. The firm has backed companies in the US and Europe, placing it at the intersection of biotech and frontier tech. The firm invests from seed through late-stage venture, often leading rounds or co-investing alongside specialized health-tech funds. Its portfolio includes companies developing epigenetic clocks, senolytic drugs that clear damaged cells, and platforms that use machine learning to repurpose existing drugs for age-related conditions. The geographic focus concentrates on the United States and Israel, two hubs where longevity science attracts both academic talent and venture dollars. The firm structures investments as direct equity, with some participation in follow-on rounds as portfolio companies advance through clinical validation. Team size and assets under management are not publicly disclosed. The firm maintains a low profile, consistent with early-stage venture managers that raise capital on a deal-by-deal or small-fund basis rather than reporting quarterly figures. It has not announced a dedicated philanthropic vehicle, though its portfolio companies often maintain academic partnerships with research institutions studying aging. The firm's principal or principals have not been named in public filings or press releases as of the latest available sourcing. What structurally distinguishes the firm is its refusal to dilute the longevity mandate into generalist health-tech. Most venture firms treat biotech and longevity as adjacency bets. Longevity Vision Holding positions them as the entire mandate. That focus requires a different underwriting model — one that assesses scientific risk on a decadal horizon, not a five-year exit window. It also constrains the universe of co-investors to those with similarly long-time-horizon capital, which is itself a filter on deal flow.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What is Longevity Vision Holding's investment thesis?
The firm invests exclusively in the longevity sector — companies that use artificial intelligence and biotechnology to extend human healthspan. Its thesis holds that aging is the primary driver of the most burdensome diseases, and that venture-scale returns are achievable by funding interventions that measure biological age, clear senescent cells, or reprogram cellular function. The firm views aging as a treatable condition rather than an immutable process, a stance that aligns it with a small set of dedicated longevity investors.
What investment stages does Longevity Vision Holding target?
The firm deploys capital from seed through late-stage venture, with early-stage investments forming the core of its activity. It leads and co-leads rounds, often alongside specialized health-tech and biotech funds. The stage-agnostic approach allows it to support companies from preclinical validation through clinical trials and toward regulatory approval, though follow-on investments depend on milestone achievement.
Which sectors does Longevity Vision Holding explicitly avoid?
The firm does not invest in generalist health-tech, traditional biotech without an aging component, or therapeutic areas unrelated to age-related disease. It also avoids sectors such as enterprise software, fintech, and consumer internet that fall outside its longevity mandate. This sector exclusion is structural — the firm positions itself as a pure-play investor, and any diversification into non-longevity areas would dilute its stated thesis.
Does Longevity Vision Holding participate in fund commitments or only direct deals?
The firm's known activity is primarily direct equity investments in operating companies. There is no public record of it acting as a fund-of-funds or making limited partner commitments to other venture managers. The deal-by-deal structure is consistent with early-stage venture firms that prefer concentrated exposure and direct governance rights in their portfolio companies.
How does Longevity Vision Holding source deal flow?
The firm sources deals through academic research networks in aging biology, longevity-focused venture conferences, and co-investor relationships with specialized health-tech funds. Key sourcing hubs include Boston, the San Francisco Bay Area, and Israel, where academic institutions produce a disproportionate share of longevity-related spinouts. The firm's concentrated thesis acts as a filtering mechanism, attracting founders who seek investors fluent in the scientific and regulatory challenges of aging interventions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: